Sign up Australia
Proactive Investors - Run By Investors For Investors

Medibio bags $13.9M to progress mental health diagnosis technology

Fidelity Investments continues to maintain a 10.6% ownership in Medibio.
human brain
Fully funded to pursue commercialisation strategy

Medibio Ltd (ASX: MEB, OTCMKTS:MDBIF) has secured firm commitments to raise $13.9 million via the placement of shares at $0.36 each to institutional investors.

Fidelity Investments followed on to maintain its 10.6% ownership in Medibio with IFM Investors and Regal FM becoming substantial shareholders post-transaction.

Medibio is a mental health technology company that uses objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions.

Sleep and other circadian measures provide a powerful lens into mental wellbeing and Medibio’s solution leverages the science linking sleep and mental health.

The company is now fully funded to pursue its aggressive commercialisation and intellectual property (IP) strategy.

The new funds will allow Medibio to build out organisational infrastructure for product commercialisation and to develop the technology platform to support commercialisation.

READ NEXT: Medibio partners with Mayo Clinic to address psychiatric conditions

Earlier this month, Medibio signed a five-year clinical trial agreement with Mayo Clinic to develop new product solutions to assist physicians in addressing psychiatric conditions.

The agreement provides for the conduct of multiple clinical trials involving the use of one or more of Medibio’s proprietary products as well as assist in future product development.

Mental health represents one of the largest clinical problem today with an estimated 350 million people word-wide suffering from depression.

According to the World Bank, depression and anxiety disorders cost the world nearly US$1 trillion annually.

Register here to be notified of future MEB Company articles
View full MEB profile View Profile

Medibio Ltd Timeline

October 11 2017
November 18 2016
November 16 2016
August 05 2016

Related Articles

Cancer cells
September 05 2017
In an initiation note on the company, finnCap’s analysts noted that ANGLE is focused on the development of Parsortix, an instrument platform with recurring revenues designed to isolate and harvest rare circulating tumour cells from a patient’s blood sample
picture of human skeleton
July 21 2017
Tissue Regenix is funding the acquisition with a placing at 10p to raise £40mln
mri scanner
July 24 2017
The Assessa PML platform is designed to facilitate the remote transfer, management and storage of MRI scans to help doctors detect progressive multifocal leukoencephalopathy

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use